Periodontal disease is one of the most prevalent chronic inflammation of oral cavity, and has been reported to be associated with atherosclerosis. In this study, we assessed the potential of orally or nasally administered recombinant HSP60 from Porphyromonas gingivalis (rGroEL) for prevention of atherosclerosis accelerated by P. gingivalis. Apolipoprotein E deficient spontaneously hyperlipidemic (Apoe shl ) mice were orally or nasally immunized with GroEL and then challenged intravenously with P. gingivalis 381. Atherosclerotic lesions in the proximal aorta of each animal were analyzed histomorphometrically, and the serum concentrations of rGroEL-specific antibodies and cytokines were determined.
Introduction
Recent studies have suggested that inflammatory and immune mechanisms activated by infectious agents are important in the development of atherosclerosis (1, 2) .
Several epidemiological studies have revealed that the host immune reaction against persistent infectious pathogens such as Chlamydia pneumoniae, P. gingivalis, and cytomegalovirus may promote the development of atherosclerosis (3, 4, 5) . In particular, immune activation by the pathogen-derived heat shock protein (HSP) GroEL may result in an autoimmune response followed by atherosclerosis via the structural similarity ormolecular mimicryof host HSP60 and GroEL. Various studies have shown that HSP60 is selectively located in atherosclerotic lesions rather than non-atherosclerotic areas of the arterial wall (6) .
Furthermore, a positive correlation exists between anti-HSP antibody levels and the severity of atherosclerosis.
High titers of anti-HSP60 antibodies have been found in patients with carotid atherosclerosis, coronary disease, and stroke (7) . HSP (GroEL) of Porphyromonas gingivalis, a major periodontal pathogen, was also suggested to be a key molecule linking periodontitis as an infectious disease with atherosclerosis as an autoimmune disease (8, 9, 10) . The central role of P. gingivalis HSP60 in the immunopathogenic mechanism of both periodontitis and atherosclerosis has been demonstrated in the context of immunodominant Tand/or B-cell epitopes (11) . A P. gingivalis HSP60 vaccine was reported to successfully reduce the level of alveolar bone loss induced by multiple periodontopathogenic bacteria (12) , and an anti-P. gingivalis HSP60 serum revealed cross-species recognition to exert an opsonophagocytic function against multiple periodontopathogenic bacteria (13). Mucosal administration of relevant autoantigens is an effective method to attenuate autoimmune diseases by inducing an unresponsive state of tolerance (14, 15) . Therefore, the present study was performed to examine whether the increasing pathogen burden of P. gingivalis into blood vessel affects the GroEL antibody levels in apoe shl mice. Further, we examined the role of mucosal delivery of GroEL in modulating inflammatory events and lesion development in atherosclerosis accelerated by P. gingivalis.
Materials and Methods
Bacterial strain P. gingivalis strain 381 was cultured on anaerobic blood agar plates (Becton Dickinson, Sunnyvale, CA) in a model 1024 anaerobic system (Forma Scientific, Marietta, OH) with 10 % H 2 , 80% N 2 , and 10 % CO 2 for 3 to 5 days. Cultures were then inoculated into brain heart infusion broth (Difco Laboratories, Detroit, MI) supplemented with 5 μg of hemin/ml and 0.4 μg of menadione/ml and grown for 2 days until reaching an optical density of 0.8 at 660 nm, corresponding to 10 9 CFU/ml. The cultured cells were then centrifuged at 8,000 × g for 20 min at 4℃ and diluted with phosphate-buffered saline (PBS) for intravenous (i. v.)
infection.
Purification of recombinant GroEL
The recombinant P. gingivalis GroEL plasmid (pRSET B-HSP60) was kindly provided by Dr. K. Yamazaki (Niigata University, Niigata, Japan) (16) . Recombinant GroEL protein was purified according to the method of Tabeta et al. challenge ( Fig. 1 ). All mice were monitored daily until sacrifice and appeared healthy throughout the course of the study. One week after the last injection, the mice were killed, and the tissue and blood samples were collected.
Quantification of the atherosclerotic lesion area
Blood was collected into heparinized syringes from the 
Statistical analysis
The data are presented as the means ± the standard errors (SE). Extent of atherosclerosis was analyzed by ANOVA (two-way) among groups and subsequently by Studentʼs paired two-tailed t-test. In all analysis, p < 0.05 was taken to indicate statistical significance.
Results
Serum GroEL-specific and HSP60-specific antibodies Nasal or oral immunization of mice with GroEL produced insufficient GroEL-specific serum IgG response under adjuvant-free condition (Fig. 2) . On the other hand, anti-GroEL antibody titer rose remarkably by P. gingivalis-challenge after immunity. The difference in final antibody titer was not seen at both immunization route. In contrast, GroEL-specific serum IgG antibodies were not detected by the non-immunized mice or P. gingivalis-challenged mice (Fig. 2) . Furthermore, we also analyzed the mean levels of anti-HSP60 antibodies in serum of mice which challenged with P. gingivalis and/or immunized with GroEL. Anti-HSP60 antibodies were not detected in any of the group (data not shown).
Histomorphometric analysis of the aortic sinus
A cryosection of the aortic sinus was examined for atherosclerotic plaque accumulation by Oil Red-O staining.
Histomorphological analysis was used to calculate the percentage of the aortic lumen occupied by atheromatous lesions. At 16 weeks, there was a notable increase in
gingivalis GroEL-specific and HSP60-specific IgG responses in serum. Apoe shl mice were orally or nasally immunized with GroEL, and then i.v. challenged with P. gingivalis as described in the legend for Fig. 1 . Serum samples were collected at 16 weeks and assessed for GroEL-specific serum IgG antibodies. The results are expressed as the mean ± SD of six mice per group. *, P < 0.05 (compared to the control group).
atherosclerotic plaque accumulations in the Apoe shl mice inoculated with P. gingivalis compared to the sham control animals (Fig. 3B, 13 gingivalis-infected mice nasally or orally immunized with GroEL ( Fig. 3A) .
Serum MCP-1 and ox-LDL levels
To further analyze the levels of systemic inflammation in the immunized animals, we measured the serum MCP-1 and ox-LDL levels in each group of mice at 16 weeks by ELISA. 
Discussion
The present study showed that increasing the pathogen burden of P. gingivalis into blood vessel enhanced inflammation and atherosclerosis in Apoe shl mice without it influences anti-GroEL antibody titer and anti-HSP60 antibody titer, which can be prevented by nasal or oral immunization with GroEL in the system different from immune tolerance.
Previous studies indicate that priming with infectious agents containing homologous HSP60, such as P. gingivalis, is involved in plaque formation and progression because of Histomorphometric analysis of the mean lesion area (B) and the percentage of the aortic sinus occupied by lesion (C) at 16 weeks. The data represent the mean ± the SD of six mice per group. *, P < 0.05 (compared to the control group). #, P < 0.05 (compared to the P. gingivalis-challenged group). the development of autoimmune reactions in the arterial wall (24, 25) . Human and microbial HSP namely share a high degree of sequence homology, which consequently may lead to misdirected autoimmunity against human self-HSP expression on stressed cells of blood vessels. On the other hand, several studies have provoked an increased interest in mucosal tolerization against HSP60 aiming to suppress atherogenesis (20, 26) . Both of these studies could successfully demonstrate a reduction in aortic plaques by this approach. Therefore, we assessed the implications of the antibodies to GroEL in P. gingivalis-induced atherosclerosis, and the potential of mucosal tolerance induction to GroEL.
It has been shown that the increased production of anti-GroEL antibodies with increasing P. gingivalis burden was associated with atherosclerosis severity (27) . These results, along with the expression of hHSP60 by cells of the lesion, support the hypothesis of molecular mimicry as a mechanism involved. However, in our study, increasing P. gingivalis burden into blood vessel did not enhance the production of anti-GroEL antibodies in serum. The elevated serum antibody titers to GroEL were not detected even in oral infection with P. gingivalis (data not shown).
Furthermore, even if there was no increase in anti-GroEL antibody titer, the significant increase in inflammation or a plaque formation occurred by P. gingivalis infection. In this study, a sufficient antibody titer over an experimental period was not obtained in mice nasally or orally immunized with GroEL only, although it has been reported that GroEL has adjuvant activity (30) . Normally, protein antigen given via the mucosal route without adjuvant has been generally reported to be only a weak immunogen and so has to been presumed to require a mucosal adjuvant to induce Ag-specific Ab responses (31) . Therefore, it is thought that high antibody titer against GroEL was obtained by the booster effect by P. gingivalis-challenge. Further, even without adjuvant, specific IgG Ab induced by the nasal or oral immunization with GroEL followed by P. gingivalis-challenge significantly diminished atherosclerotic plaque accumulation, MCP-1, and ox-LDL levels accelerated by P. gingivalis.
It has been shown that patients with periodontitis had higher concentrations of circulating HSP60 than controls (32) . Further, it appears that there is a very strong correlation between HSP60 and small, dense LDL from the following reasons. To the first, the lectin-like oxidized low-density lipoprotein receptor 1 of macrophage was suggested to be a specific receptor for HSP60 that binds the chaperonin via its C terminus (33) weeks. The data represent the mean ± the SD for six mice per group. *, P < 0.05 (compared to the control group). #, P < 0.05 (compared to the P. gingivalis-challenged group).
peptide antigen significantly reduced early atherosclerotic lesions in a mouse model (34) . The third, HSP60 was found to regulate some functions of oxidized LDL such as modulation of F-actin capping proteins involved in actin polymerization and macrophage motility (35) . Since our previous studies also indicate that periodontal pathogens can accelerate atherosclerosis in Apoe shl mice by inducing HSP60 expression in aorta (36, 37) , it may say that circulating HSP 60 could play a role in chronic inflammation and could become target for therapeutic measures aiming at reducing the risk of atherogenic dyslipidemia and its complications.
In conclusion, our result showed that the pathogen burden 
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